Other Clinical Trial - Early Detection of Advanced Fatty Liver Disease

Status Completed

Clinical Trial Summary

Non-alcoholic fatty liver disease is the most common cause of chronic liver disease in the western world, affecting one in every three subjects. The investigators hypothesize that a patient population without known liver disease has a certain percentage of patients with liver fibrosis who are undiagnosed and not monitored.

Clinical Trial Description

The investigators will run an algorithm for the non-invasive diagnosis of advanced fibrosis in non-alcoholic fatty liver disease on a participants without known liver disease. Nafld Score and Elastography are now being used to predict the severity of liver fibrosis and deciding whether the patient is going to a biopsy, clinical follow-up or further investigation of liver cirrhosis and complications. The detection of participants with Nafld Score more than 0.675 (advanced fibrosis) will enroll them to an elastography test. Participants with advanced fibrosis according to elastography will be introduced to follow-up and treatment that should delay or prevent progression of the disease to more advanced conditions like: cirrhosis, portal hypertension, esophageal varicose veins and hepatocellular carcinoma. If the investigators find that the results of the study are consistent with their hypothesis, this will lead to applying the flowchart to a larger sample of population in order to use it as a future survey. Moreover, the investigators will check whether there is a correlation between Nafld Score and elastography in participants without know liver disease with Nafld Score more than 0.675. ;

Study Design

Related Conditions & MeSH terms

Fatty Liver
Liver Cirrhosis
Liver Diseases
Liver Fibrosis
Non-alcoholic Fatty Liver Disease

Clinical Trial Details

NCT number	NCT03608748
Study type	Observational
Source	HaEmek Medical Center, Israel
Contact
Status	Completed
Phase
Start date	November 1, 2018
Completion date	March 1, 2023

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05480696` - Soluble Fibre Supplementation in NAFLD	Phase 1
Active, not recruiting	`NCT02500147` - Metformin for Ectopic Fat Deposition and Metabolic Markers in Polycystic Ovary Syndrome (PCOS)	Phase 4
Completed	`NCT04671186` - Role of Probiotics in Treatment of Pediatric NAFLD Patients by Assessing With Fibroscan	N/A
Recruiting	`NCT05979779` - Ph 2 Study of the Safety and Efficacy of Three HU6 Dose Levels and Placebo in Nonalcoholic Steatohepatitis	Phase 2
Recruiting	`NCT05462353` - Study to Evaluate the Safety, Tolerability, and Efficacy of ASC41 Tablets in Adult Patients With NASH	Phase 2
Completed	`NCT05006885` - ALT-801 in Diabetic and Non-Diabetic Overweight and Obese Subjects With Non-alcoholic Fatty Liver Disease (NAFLD)	Phase 1
Completed	`NCT04117802` - Effects of Maple Syrup on Gut Microbiota Diversity and Metabolic Syndrome	N/A
Recruiting	`NCT04365855` - The Olmsted NAFLD Epidemiology Study (TONES)	N/A
Recruiting	`NCT05618626` - Prevention of NAFLD and CVD Through Lifestyle Intervention	N/A
Completed	`NCT03256526` - 6-week Safety and PD Study in Adults With NAFLD	Phase 2
Enrolling by invitation	`NCT06152991` - Clinical Trial Assessing Godex Carnitine Orotate Complex in Nonalcoholic Fatty Liver Disease Patients for Efficacy	Phase 3
Completed	`NCT03681457` - Evaluation of the Pharmacokinetics of Tropifexor in Subjects With Mild, Moderate, or Severe Hepatic Impairment Compared to Healthy Control Subjects	Phase 1
Completed	`NCT06244550` - Clinical Trials Using HepatoKeeper Herbal Essentials to Treat Non-alcoholic Fatty Liver Disease and Metabolic Factors	N/A
Not yet recruiting	`NCT05120557` - Point-of-care Ultrasound Screening and Assessment of Chronic Liver Diseases and NASH	N/A
Completed	`NCT03060694` - Screening Diabetes Patients for NAFLD With Controlled Attenuation Parameter and Liver Stiffness Measurements
Completed	`NCT02526732` - Hepatic Inflammation and Physical Performance in Patients With NASH	N/A
Recruiting	`NCT01988441` - The Influence of Autophagy on Fatty Liver
Recruiting	`NCT01680003` - Hepar-P Study to Evaluate the Safety and Efficacy of a Standardised Extract of Phyllanthus Niruri for the Treatment of Non-alcoholic Fatty Liver Disease	Phase 2
Completed	`NCT01712711` - Helicobacter Pylori Eradication in Diabetic Subjects With Non-alcoholic Fatty Liver Disease	Phase 2
Recruiting	`NCT00941642` - Placebo Controlled Study Using Lovaza as Treatment for Non-Alcoholic Fatty Liver Disease	Phase 4